Published in PLoS One on September 12, 2013
Genome-wide association study of toxic metals and trace elements reveals novel associations. Hum Mol Genet (2015) 0.93
A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients. PLoS One (2014) 0.83
Liquid biopsies in patients with diffuse glioma. Acta Neuropathol (2015) 0.82
Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. PLoS One (2014) 0.79
Antiangiogenic therapy of brain tumors: the role of bevacizumab. Neurol Sci (2014) 0.78
Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Oncotarget (2016) 0.78
Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: A critical evaluation. Mol Clin Oncol (2016) 0.76
CD109 Mediates Cell Survival in Hepatocellular Carcinoma Cells. Dig Dis Sci (2016) 0.76
Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma. Oncotarget (2016) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology (2008) 8.10
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J (1999) 6.62
PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol (2005) 4.57
The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer (2006) 4.55
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med (2012) 3.62
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48
Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol (2007) 3.42
Genes that distinguish physiological and pathological angiogenesis. Cancer Cell (2007) 3.35
Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol (2010) 3.07
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol (2010) 2.46
Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20
Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res (2009) 2.00
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol (2010) 1.91
Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol (2010) 1.73
Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood (2011) 1.66
Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol (2004) 1.64
VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med (2008) 1.54
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anticancer Drugs (2012) 1.50
Radiographic patterns of relapse in glioblastoma. J Neurooncol (2010) 1.47
Isolation and characterization of endothelial progenitor cells from human blood. Curr Protoc Stem Cell Biol (2008) 1.36
Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep (2011) 1.34
Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer (2011) 1.28
Application of polychromatic flow cytometry to identify novel subsets of circulating cells with angiogenic potential. Cytometry A (2010) 1.22
Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw (2011) 1.19
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol (2012) 1.17
Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood (2002) 1.15
The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors. Biochim Biophys Acta (2011) 1.14
Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin. Cancer Res (2011) 1.09
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res (2009) 1.07
Hematopoietic stem cell-derived pericytic cells in brain tumor angio-architecture. Stem Cells Dev (2008) 1.04
Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg (2010) 1.03
Bevacizumab for malignant gliomas. Arch Neurol (2010) 1.02
Expression of CD109 in human cancer. Oncogene (2004) 1.00
CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol (1999) 0.99
Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer (2012) 0.97
Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS One (2012) 0.97
Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol (2011) 0.93
Circulating perivascular progenitors: a target of PDGFR inhibition. Int J Cancer (2011) 0.86
Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol (2010) 0.85
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol (2011) 0.85
The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab. Ann Oncol (2010) 0.82
Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: Study of their clinical significance. Exp Ther Med (2011) 0.80
Circulating endothelial cells as biomarkers for patients receiving bevacizumab. Lancet Oncol (2011) 0.79
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer (2006) 4.55
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res (2003) 3.09
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer (2008) 2.45
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol (2008) 2.10
Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res (2009) 2.00
Conversion of the BASE prion strain into the BSE strain: the origin of BSE? PLoS Pathog (2007) 1.97
Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells (2009) 1.95
Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol (2006) 1.92
Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res (2006) 1.89
Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet (2011) 1.83
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood (2005) 1.80
Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. J Med Genet (2009) 1.79
Is fluorescein-guided technique able to help in resection of high-grade gliomas? Neurosurg Focus (2014) 1.74
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol (2007) 1.73
Postinfectious neurologic syndromes: a prospective cohort study. Neurology (2013) 1.73
Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost (2005) 1.73
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood (2006) 1.69
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol (2010) 1.63
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol (2007) 1.59
Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology (2009) 1.56
High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res (2009) 1.53
CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res (2002) 1.52
Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymus. Bone (2006) 1.49
Autologous peripheral blood stem cell transplantation for myocardial regeneration: a novel strategy for cell collection and surgical injection. Ann Thorac Surg (2004) 1.48
An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci U S A (2012) 1.45
Acute late-onset encephalopathy after radiotherapy: an unusual life-threatening complication. Neurology (2013) 1.42
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast (2012) 1.39
Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. Plast Reconstr Surg (2017) 1.38
The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression. Cancer Res (2011) 1.37
Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: preliminary results in 12 cases. Acta Neurochir (Wien) (2013) 1.34
Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res (2005) 1.32
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol (2003) 1.30
Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today (2007) 1.29
Toll receptor-mediated regulation of NADPH oxidase in human dendritic cells. J Immunol (2004) 1.29
Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res (2003) 1.23
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res (2012) 1.21
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res (2009) 1.20
Diagnostic potential of autofluorescence for an assisted intraoperative delineation of glioblastoma resection margins. Photochem Photobiol (2003) 1.19
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res (2007) 1.19
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res (2006) 1.18
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. Blood (2006) 1.17
Circulating endothelial cells as biomarkers in clinical oncology. Microvasc Res (2010) 1.17
A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med (2008) 1.16
NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget (2012) 1.15
Unique regulation of CCL18 production by maturing dendritic cells. J Immunol (2003) 1.14
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res (2011) 1.13
Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl Acad Sci U S A (2008) 1.13
Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol (2010) 1.13
Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res (2011) 1.12
Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen (2009) 1.12
Chronic migraine with medication overuse pre-post withdrawal of symptomatic medication: clinical results and FMRI correlations. Headache (2010) 1.12
Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. Neuro Oncol (2007) 1.10
The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. Neurobiol Dis (2005) 1.08
Deciphering the 8q24.21 association for glioma. Hum Mol Genet (2013) 1.08
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res (2009) 1.07
Neuroradiological diagnosis of Chiari malformations. Neurol Sci (2011) 1.07
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. Blood (2004) 1.07
Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer (2004) 1.06
About CD45-/CD31+/CD105+ circulating cells in patients with gynecologic malignancies--letter. Clin Cancer Res (2014) 1.06
Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. Neurosci Lett (2004) 1.05
Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer. Cancer Res (2013) 1.05
Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring) (2009) 1.04
Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol (2002) 1.04